海思科医药集团股份有限公司关于部分5%以上股东之一致行动人股份减持计划的预披露公告

Core Viewpoint - The announcement details a share reduction plan by significant shareholders of Haishike Pharmaceutical Group Co., Ltd., indicating a total potential reduction of up to 10,000,000 shares, which is approximately 0.89% of the company's total share capital [2][3]. Group 1: Shareholder Information - Shareholder Hao Congmei holds 3,518,000 shares, representing 0.31% of the total share capital, while shareholder Yang Fei holds 42,442,286 shares, representing 3.79% of the total share capital [2]. - The reduction plan involves Hao Congmei planning to reduce up to 2,000,000 shares (0.18% of total share capital) and Yang Fei planning to reduce up to 8,000,000 shares (0.71% of total share capital) [3]. Group 2: Reduction Plan Details - The reduction will occur within three months following a 15 trading day period after the announcement, using block trades or centralized bidding [2][3]. - The reason for the reduction is stated as personal funding needs [3]. - The shares to be reduced were originally acquired through block trades in 2015 [3]. Group 3: Compliance and Commitments - The shareholders have committed to avoiding any competition with the company's main business and ensuring that any related transactions are conducted fairly and transparently [5]. - The shareholders confirm that there are no circumstances that would prevent them from reducing their shares as per the regulations [5].